Country
United Kingdom
Avacta Group Plc, which is developing a new type of protein therapeutic, is to license certain assets to Moderna Therapeutics Inc against a potential therapeutic target which has been part of an ongoing research collaboration between the two companies.
Full text available to subscribers only. Click here for information on subscribing to MedNous.